Hologic

Steve MacMillan, Chairman, President, and CEO, leads the executive team responsible for capital allocation at Hologic. Strategic moves such as the 2012 Gen-Probe acquisition and the purchase and subsequent divestiture of Cynosure in 2017 were executed under his leadership. The company reinvests profit into internal R&D and M&A for women's health technologies.

Hologic combines internal R&D with a systematic M&A strategy focused on companies developing women's health diagnostics, imaging, and surgical tools. Its 4,100-plus patent portfolio reflects both organic invention and acquired intellectual property. The company also collaborates with clinicians and researchers to validate new applications, such as its recent study using Genius AI Detection to identify invasive lobular cancers.

Hologic reports revenue through diagnostics, breast health, and surgical segments. Diagnostics includes molecular assays on the Panther platform for HPV and STIs, breast health is led by the Genius 3D Mammography franchise, and surgical encompasses NovaSure and MyoSure devices. The sale of the Cynosure medical aesthetics business in 2019 refocused the company entirely on core women's health.

Hologic operates corporate philanthropy through the Hologic Global Women's Health Index, conducted annually with Gallup, and Project Health Equity, which funds cancer screening and care for underserved women. These initiatives are corporate programs directed from the company's executive office, not independent charitable entities, and are funded from Hologic's operating budget.

Hologic's products are primarily FDA-cleared medical devices and tests that rely on physician adoption and payer coverage. Its mammography systems require facility accreditation and its molecular diagnostics depend on clinical guidelines from bodies such as the American College of Obstetricians and Gynecologists. The company's recent emphasis on AI-driven cancer detection represents a regulatory pathway managed through 510(k) clearances.